Nicotinamide N-methyltransferase (NNMT): A key enzyme in cancer metabolism and therapeutic target.
Cancer
Homocysteine (Hcy)
Metabolism
Nicotinamide N-methyltransferase (NNMT)
Nicotinamide adenine dinucleotide (NAD(+))
Target
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
22 Sep 2024
22 Sep 2024
Historique:
received:
20
08
2024
revised:
17
09
2024
accepted:
17
09
2024
medline:
24
9
2024
pubmed:
24
9
2024
entrez:
23
9
2024
Statut:
aheadofprint
Résumé
Emerging research has positioned Nicotinamide N-methyltransferase (NNMT) as a key player in oncology, with its heightened expression frequently observed across diverse cancers. This increased presence is tightly linked to tumor initiation, proliferation, and metastasis. The enzymatic function of NNMT is centered on the methylation of nicotinamide (NAM), utilizing S-adenosylmethionine (SAM) as the methyl donor, which results in the generation of S-adenosyl-L-homocysteine (SAH) and methyl nicotinamide (MNAM). This metabolic process reduces the availability of NAM, necessary for Nicotinamide adenine dinucleotide (NAD
Identifiants
pubmed: 39312861
pii: S1567-5769(24)01730-2
doi: 10.1016/j.intimp.2024.113208
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
113208Informations de copyright
Copyright © 2024 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.